Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Aclaris Therapeutics, Inc is a biotechnology business based in the US. Aclaris Therapeutics shares (ACRS) are listed on the NASDAQ and all prices are listed in US Dollars. Aclaris Therapeutics employs 75 staff and has a trailing 12-month revenue of around USD$6 million.
Since the stock market crash in March caused by coronavirus, Aclaris Therapeutics's share price has had significant positive movement.
Its last market close was USD$4.51, which is 67.85% up on its pre-crash value of USD$1.45 and 544.29% up on the lowest point reached during the March crash when the shares fell as low as USD$0.7.
If you had bought USD$1,000 worth of Aclaris Therapeutics shares at the start of February 2020, those shares would have been worth USD$713.59 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$3,523.44.
|Latest market close||USD$4.51|
|52-week range||USD$0.7 - USD$5.04|
|50-day moving average||USD$3.8161|
|200-day moving average||USD$2.4036|
|Wall St. target price||USD$4.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.168|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-19)||45.95%|
|1 month (2020-10-26)||10.00%|
|3 months (2020-08-26)||87.92%|
|6 months (2020-05-26)||241.67%|
|1 year (2019-11-26)||171.69%|
|2 years (2018-11-26)||-47.13%|
|3 years (2017-11-24)||-80.62%|
|5 years (2015-11-25)||-80.72%|
|Revenue TTM||USD$6 million|
|Gross profit TTM||USD$-63,611,000|
|Return on assets TTM||-27.72%|
|Return on equity TTM||-90.46%|
|Market capitalisation||USD$132.6 million|
TTM: trailing 12 months
There are currently 682,337 Aclaris Therapeutics shares held short by investors – that's known as Aclaris Therapeutics's "short interest". This figure is 5.7% up from 645,385 last month.
There are a few different ways that this level of interest in shorting Aclaris Therapeutics shares can be evaluated.
Aclaris Therapeutics's "short interest ratio" (SIR) is the quantity of Aclaris Therapeutics shares currently shorted divided by the average quantity of Aclaris Therapeutics shares traded daily (recently around 637698.13084112). Aclaris Therapeutics's SIR currently stands at 1.07. In other words for every 100,000 Aclaris Therapeutics shares traded daily on the market, roughly 1070 shares are currently held short.
However Aclaris Therapeutics's short interest can also be evaluated against the total number of Aclaris Therapeutics shares, or, against the total number of tradable Aclaris Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aclaris Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Aclaris Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0167% of the tradable shares (for every 100,000 tradable Aclaris Therapeutics shares, roughly 17 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aclaris Therapeutics.
Find out more about how you can short Aclaris Therapeutics stock.
We're not expecting Aclaris Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Aclaris Therapeutics's shares have ranged in value from as little as $0.7 up to $5.04. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aclaris Therapeutics's is 1.1477. This would suggest that Aclaris Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Everything we know about the Qilian International Holding Group IPO, plus information on how to buy in.
Everything we know about the AbCellera Biologics IPO, plus information on how to buy in.
Steps to owning and managing CALM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BG, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCLI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLBD, with 24-hour and historical pricing before you buy.
Steps to owning and managing BDTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RILYO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASPN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.